New oral non-sedating antihistamines represent an important breakthrough in the pharmacological treatment of allergic diseases, including allergic rhinitis and chronic urticaria.
A series of controlled clinical trials have demonstrated the efficacy of bilastine in allergic rhinitis, as determined by improvements in all nasal and ocular symptoms and patient quality of life (QoL).
The first speaker in this symposium is Professor Martin Church, who will provide a general overview of the main safety and efficacy requirements for an ideal H1 antihistamine and outline the progress made with the most recent generation in comparison with older H1 antihistamines.
